The company opens a bioanalytical lab in the US, which offers an additional 59,000-square-feet of space to the overall facility, making it “one of the largest laboratories of its kind.”
Contract development and manufacturing organization (CDMO), Recipharm, has invested in a new high speed filling line for pre-filled syringes and cartridges at its facility in Wasserburg, Germany.
Bavarian Nordic has entered into an agreement with Grand River Aseptic Manufacturing (GRAM), a US based contract manufacturer, for fill and finish of the Jynneos smallpox/monkeypox vaccine in the country.
Bavarian Nordic A/S has received approvals from the US and EU regulatory authorities to manufacture its Jynneos/Imvanex smallpox and monkeypox vaccine at its fill and finish facility in Denmark.
CDMO WuXi Biologics will invest $1.4bn in a 10 year investment plan to expand its research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore.
Merck is collaborating with Agilent Technologies to plug what it calls a critical gap within downstream processing for process analytical technologies (PAT).
Charles River Laboratories International and ASC Therapeutics have announced plans to manufacture ASC618, a second-generation gene therapy for hemophilia A.
Flow Eighteen38, a protein sciences division created to facilitate and accelerate antibody characterization and protein purification projects, has announced a €5m ($5.58m) investment into its protein production and biophysical characterization capabilities...
Moderna and Thermo Fisher Scientific have announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing of COVID-19 vaccine Spikevax in the US, as well as other investigational mRNA vaccines and therapies.
Valneva has been awarded up to £20m ($27m) in R&D funding from Scottish Enterprise: which will be used to revive its plans to increase vaccine manufacturing in Scotland.
Cryoport, Inc. has entered into a partnership with specialized Belgian CDMO, Cell Matters, to deliver end-to-end cryopreservation services for leukapheresis derived therapies supporting both autologous and allogeneic cell therapies.
Contract development and manufacturing organization (CDMO), Recipharm, says it has inked a deal with a top 10 big pharma company to support vaccine manufacturing from its facility in Kaysersberg, France.
Contract packaging and clinical supply services company Sharp has completed the construction of new purpose-built production suites to facilitate the packaging, storage and distribution of gene therapies at its facility in Heerenveen, The Netherlands.
Automated cell therapy manufacturing processes could reduce manual intervention and human errors, enabling more robust processes, improved product quality, and lower costs.
Adeno-associated virus (AAV) hold potential for use in numerous gene therapies: with demand only set to grow as more therapies are developed and approved. However, supply of AAV is one of the challenges for the sector. In a study published in Biotechnology...
Downstream biomanufacturing is expected to witness a high CAGR over the next 10 years: driven by continuous product innovations in chromatography product lines and filtration systems.
Lonza has signed a licensing agreement with clinical-stage biopharma, Zhejiang Doer Biologics, whereby the Hangzhou, China based biopharma company will develop multi-specific biotherapeutics using the Swiss CDMO’s XS Pichia.
Moderna and the Australian government have announced an agreement in principle to build a mRNA vaccine manufacturing facility in Victoria, Australia: providing up to 100 million doses a year.
Several contract development and manufacturing organization (CDMO) supported biopharma projects have been flagged in the past month. We take a closer look.
The vacuum filtration units are suitable for lab-based research in low volumes, with the company stating the update improves speed, capacity, and stability.
From industrializing mRNA manufacture to the implications of a potential IP waiver on COVID-19 vaccine production, hear from the experts in our free webinar this week.
Waters has announced a five-year investment to develop new analytical technology for bioprocessing and biomanufacturing with the University of Delaware.
Novartis has signed a new initial agreement with BioNTech for COVID-19 vaccine manufacturing: with its sterile manufacturing facilities in Ljubljana, Slovenia, to fill at least 24 million doses in 2022.
Cytiva, in collaboration with China's Wego Pharmaceutical Co Ltd, is expanding manufacturing capacity for bioprocessing single-use consumables in China.
Ardena has acquired Idifarma, a contract manufacturer of niche and highly potent generic and innovative drugs, from Suanfarma; the deal enables it to expand across Southern Europe and supports its strategy to become a leading global CDMO.
A new partnership promises improved biomanufacturing processes for gene therapies; the goal is to support the sector in scaling up through more efficient, cost-effective processes.
South African biopharmaceutical company The Biovac Institute will manufacture and distribute Pfizer and BioNTech’s COVID-19 vaccine in Africa, with the three companies signing a letter of intent this week.
Coriolis Pharma has announced a 7,800-meter-square expansion to a building situated in Munich, Germany, where the company is headquartered, that will host formulation development for advanced therapeutic medicine products (ATMPs).
Becton, Dickinson and Company (BD) is to build a new plant in Zaragoza, Spain, with an investment of €165m (US$200m). The site will produce glass pre-filled syringes and plastic components.
Excipient producer, DFE Pharma, is expanding its reach, capitalizing on increasing growth in the biologics sector, and launching a new sucrose stabilizer.
BioNTech plans to expand its global footprint with a regional headquarters for South East Asia in Singapore; as well as a fully integrated mRNA manufacturing facility.
Ontario-based, Nicoya Lifesciences, is in the process of completing a prototype of a low-cost, single-use device that tests for active SARS-CoV-2 infection, variants and, eventually, other viruses. The novel test is called Atlas.
A new report published by Meticulous Research shows the continuous bioprocessing market is expected to grow at a CAGR of 22.9% from 2020 to 2027 to reach US$197.8m by the end of the period.
